Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions

Teva Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: Estradiol/Norethindrone acetate

Drug: Activella®

Study type

Interventional

Funder types

Industry

Identifiers

NCT01181726

3252

Details and patient eligibility

About

The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.

Full description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

Enrollment

40 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Non-smoking or smoking (up to 10 cigarettes/day), physiologically or surgically post-menopausal female within the age range of 18-65 years.
17β-estradiol serum levels of ≤ 92 pmol/L and follicle-stimulating hormone (FSH) of ≥ 40 IU/L.
Body Mass Index (BMI) greater than or equal to 19.0 kg/m2 and less than or equal to 30.0 kg/m2.
Normal findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs.
Hemoglobin ≥ 115 g/L.
Normal pap smear.
Normal mammogram within 1 year for subjects who are over the age of 50 years.
Negative for drugs of abuse and alcohol.
Negative for hepatitis B-surface antigen, hepatitis C, and Human Immunodeficiency Virus (HIV).
No clinical laboratory values outside the acceptable range unless the Principal Investigator or Sub-Investigator decides that they are not clinically significant (NCS).
Negative for pregnancy.
Subjects who are surgically post-menopausal with an intact uterus (i.e. bilateral oophorectomy) for at least 6 months, or physiologically post-menopausal (i.e. spontaneous amenorrhea) for at least 1 year, and who will adhere to contraceptive requirements from at least 10 days before Period I check-in, during the study and up until 1 month after the end of the study.
Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF.

Exclusion criteria

Known history of hypersensitivity to norethindrone and estradiol combinations and/or norethindrone, and/or estradiol.
Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, or hematological diseases, malignancies, or migraines, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
Known history of liver, kidney, and/or gallbladder dysfunction/disease, chronic diarrhea, or inflammatory bowel diseases.
Known history or presence of cerebrovascular diseases or venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
Any history of stroke.
Presence of any significant physical or organ abnormality.
History of osteoporosis.
History or presence of fibrocystic breast disease.
History or presence of breast, endometrial, cervical, and/or uterine carcinoma.
Any illness during the 4 weeks before this study, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
Any history or evidence of psychiatric or psychological disease, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
Any history or abnormal vaginal bleeding, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
Any history of asthma (after 12 years of age).
Evidence of pregnancy or lactation.
Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
Any history or drug abuse.
Any recent history of alcohol abuse (less than 1 year).
Use of any prescription medication within 30 days preceding this study.
Use of hormone replacement therapy within 30 days before drug administration.
Use of over-the-counter (OTC) medication or any herbal supplement within the 7 days preceding this study.
Use of hormonal contraceptives, oral, transdermal, implant within 30 days before drug administration or a depot injection or progestogen drug within 1 year before the drug administration.
Depot injection of any drug within 6 months.
Blood draws within 56 days preceding this study, during the conduct of any clinical study at another facility, or within the lockout period specified by previous study.
Blood donations within 56 days preceding this study.
Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
Participation in a clinical trial with an investigational drug within 30 days preceding this study.
Intolerance to venipuncture.